TIẾP CẬN CHẨN ĐOÁN VÀ CHIẾN LƯỢC ĐIỀU TRỊ BỆNH NHÂN TRẦM CẢM KHÁNG TRỊ

Thiện Nguyễn Hữu; Ca Nguyễn Văn; Khang Đặng Trần; Ninh Đinh Vũ Ngọc; Tuấn Hoàng Quang; Chân Đặng Văn

Keywords:

major depressive disorder, treatment resistant depression, chemotherapy, electroconvulsive therapy, , repetitive transcranial magnetic stimulation, deep brain stimulation

Abstract

Treatment resistant depression is a major depressive disorder that does not respond to conventional therapy. Authors have different perspectives on treatment resistant depression, but fundamentally, treatment resistant depression does not fully respond to at least two antidepressants. Treatment therapies include changing and combining antidepressants, chemotherapy enhancement such as lithium salt, triiodothyronine, new generation antipsychotics. There are also brain stimulant therapies that include electroconvulsive therapy, repetitive transcranial magnetic stimulation, deep brain stimulation, Vegus stimulation and magnetic seizure therapy. Therapies with little data mentioned include the using of ketamine, psilocybin, and anti-inflammatories, corticoid, etc. In this article, we would like to give an overview as well as a correct diagnostic and effective strategies for treatment resistant depression.

References

Cao Tiến Đức, Bùi Quang Huy, Nguyễn Văn Ngân và cs (2016), “Giáo trình bệnh học Tâm thần”, Nhà xuất bản Quân đội nhân dân, 285-238

Sadock B. J., Sadock V. A., Ruiz P. et al (2015), “Mood disorder”, Kaplan and Sadock’s Synopsis of psychiatry, eleventh edition, Williams and Wilkins, 331-361.

Taylor D. M., Barnes T. R. E., Young A. H. et al, (2018), “The Mausley Prescribing Guidelines in Psychiatry thirteenth edition” Wiley Blackwell, 267- 277

Rush A. J., Trivedi M. H., Wisniewski S. R., et al. (2006), “Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report”, Am J Psychiatry, 163(11):1905–1917

Voineskos D., Daskalakis Z. J., Blumberger D.M. (2020), “Management of Treatment-Resistant Depression: Challenges and Strategies”, Neuropsychiatr Dis Treat, 16: 221–234.

Thase M. E., Rush A. J., Howland R. H., et al. (2002), “Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression”. Arch Gen Psychiatry, 59(3):233–239.

Shelton R. C., Tollefson G. D., Tohen M., et al (2001), “A novel augmentation strategy for treating resistant major depression”, Am J Psychiatry, 158(1):131–134.

El-Khalili N., Joyce M., Atkinson .S, et al (2010), Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study” Int J Neuropsychopharmacol, 13(7):917–932

Berlim M.T., Van den E. F., Tovar-Perdomo S., et al (2014), “Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials”, Psychol Med, 44(2):225––39

Carhart-Harris R. L., Bolstridge M., Rucker J., et al (2016), “Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study”, Lancet Psychiatry, 3(7):619–627.